EUCTR2010-021220-10-GB进行中（未招募）不适用
A Randomised Double-blind Phase IIa Study (with Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination with Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients with FGFR1 Polysomy or Gene Amplification Who Have Progressed Following Treatment with Prior Endocrine Therapy (Adjuvant or First-line Metastatic) (GLOW) - GLOW
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Post-menopausal women (either through bilateral oophorectomy or amenorrhoeic for 24 months)
- •Histological confirmation of Breast Cancer with documented ER+ receptor status
- •Safety run-in: Relapsing during/within 12 months of completion of a single regimen of adjuvant endocrine therapy with non-steroidal AI and/ tamoxifen or progression following 1st line endocrine therapy with non-steroidal AI
- •Randomised phase IIa: Received at least 1 prior endocrine therapy in the metastatic setting or have relapsed during/ within 6 months of completion of adjuvant endocrine therapy (either non-steroidal AI or tamoxifen or a combination of both). Chemotherapy administered in the adjuvant setting is permitted.
- •Randomised phase IIa: Mandatory provision of tumour sample to confirm FGFR1 polysomy or gene amplification
- •At least one measurable lesion that can be accurately assessed by CT/MRI/x-ray at baseline and follow up visits
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Prior exposure to exemestane (safety run-in) / fulvestrant (randomised phase IIa), or any agent known to inhibit FGFRs.
- •More than 1 prior regimen of chemotherapy for breast cancer
- •ECG recordings that demonstrate significant abnormalities in cardiac rate, rhythm or conduction
- •History of hypersensitivity to active or inactive excipients of AZD4547 or exemestane (safety run-in ) or fulvestrant (Randomised phase), including castor oil, or drugs with a similar chemical structure or class to AZD4547 or exemestane or fulvestrant.
- •Randomised phase IIa: bleeding/blood clotting conditions that would prevent the administration of the fulvestrant injection into the buttocks
研究者
相似试验
进行中（未招募）
不适用
Safety and efficacy of AZD4547 in combination with fulvestrant vs. fulvestrant alone in ER+ Breast Cancer patientsER+ Breast cancerMedDRA version: 16.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021220-10-HUAstraZeneca AB120
进行中（未招募）
不适用
Safety and efficacy of AZD4547 in combination with exemestane vs. exemestane alone in ER+ Breast Cancer patientsEUCTR2010-021220-10-DEAstraZeneca AB89
进行中（未招募）
不适用
A Randomised Double-blind Phase IIa Study (with Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination with Exemestane vs. Exemestane Alone in ER+ Breast Cancer Patients with FGFR1 Polysomy or Gene Amplification Who Have Progressed Following Treatment with One Prior Endocrine Therapy (Adjuvant or First-line Metastatic). - NDBreast CancerEUCTR2010-021220-10-ITASTRAZENECA72
进行中（未招募）
不适用
A Randomised Double-blind Phase IIa Study (with Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination with Exemestane vs. Exemestane Alone in ER+ Breast Cancer Patients with FGFR1 Polysomy or Gene Amplification Who Have Progressed Following Treatment with One Prior Endocrine Therapy (Adjuvant or First-line Metastatic)MedDRA version: 12.1Level: LLTClassification code 10006187Term: Breast cancerBreast CancerEUCTR2010-021220-10-FRAstraZeneca AB72
进行中（未招募）
不适用
A Randomised Double-blind Phase IIa Study (with Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination with Exemestane vs. Exemestane Alone in ER+ Breast Cancer Patients with FGFR1 Polysomy or Gene Amplification Who Have Progressed Following Treatment with One Prior Endocrine Therapy (Adjuvant or First-line Metastatic)Breast CancerEUCTR2010-021220-10-CZAstraZeneca AB72